NEXENTIS TECHNOLOGIES INC. Net Fee Amt
NEXENTIS TECHNOLOGIES INC. (NXTS) had Net Fee Amt of $1.29 thousand as of 2026-07-13, per its S-1 filed 2026-07-13.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-13
- 2026-07-13: Net Fee Amt $1.29K.
- 2026-04-16: Net Fee Amt $4.98K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-13 | $1.29K S-1 · filed 2026-07-13 |
| 2026-04-16 | $4.98K S-3 · filed 2026-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |